Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A

6(85.7%)

Phase 2

1(14.3%)

7Total

N/A(6)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04094454Not ApplicableRecruiting

Intrafractional Vaginal Dilation in Anal Cancer Patients Undergoing Pelvic Radiotherapy

Role: lead

NCT06142760Not ApplicableRecruiting

MR-guidance in Chemoradiotherapy for Cervical Cancer

Role: lead

NCT05671458Not ApplicableRecruiting

Multiparametric Imaging-based Intraoperative Navigation for Guidance of Surgical Resection and Postoperative Radiotherapy in Patients With Head-and-neck Tumors

Role: lead

NCT04218019Not ApplicableWithdrawn

Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation

Role: lead

NCT03297788Not ApplicableCompleted

Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain Metastases

Role: lead

NCT03285932Phase 2Completed

Stereotactic Radiotherapy of the Resection Cavity of Brain Metastases vs. Post-operative Whole-brain Radiotherapy

Role: lead

NCT03303365Not ApplicableCompleted

Cyberknife Radiosurgery for Patients With Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence

Role: lead

All 7 trials loaded